Nusano to Present Production Capabilities to European Radiopharmaceuticals Working Gr

[admin]

Proprietary ion source and beam technology capable of producing approximately 10 times the current global supply of Astatine-211WEST VALLEY CITY, Utah, May 01, 2023 (GLOBE NEWSWIRE) -- Nusano, Inc., a medical technology company reshaping the production of cancer-fighting radioisotopes, today announced Gregory Moffitt, PhD, Director of Target Development at Nusano, will present an overview of the company’s breakthrough production platform to the European Cooperation in Science and Technology (COS